Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: The motion curves of rats in the spatial probe test (SPT) of rats in the five groups Note: Group A, blank control group; Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; Group E, PI3K/Akt agonist group.

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Single-particle Tracking

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: Histopathologic changes in the hippocampal tissue detected by HE staining Note: Group A, blank control group; Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; Group E, PI3K/Akt agonist group.

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Staining

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: Expression of PI3K-AKT-mTOR pathway proteins in the cerebral cortex A. , hippocampus B. , cerebellum C. , brain stem D. , and thalamus E. of rats among the five groups. Note: Group A, blank control group; Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; Group E, PI3K/Akt agonist group.

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Expressing

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: The proportion of δ waves in electrocorticogram (ECoG) of rats in the five groups before and after drug administration Note: Group A, blank control group; Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; Group E: PI3K/Akt agonist group. A: 5 min before drug administration; B: 5 min after drug administration; The superscript lowercase letters ( a, b, c, d, e ) represent the pairwise comparison among the five groups with the same protein and tissue. The same superscript lowercase letter indicated the P > 0.05, and the different superscript lowercase letter indicated the P

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques:

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: The comparisons of the duration of loss of righting reflex (LORR) and ataxic period of anesthetized rats among the three groups Note: Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; A: comparison of the duration of LORR; B: comparison of the ataxic period; # , compared with Group B, P

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques:

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: Graph of the average escape latency (EL) of rats in the place navigation test Note: Group A, blank control group; Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; Group E, PI3K/Akt agonist group.

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques:

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: The mRNA expression in the PI3K-AKT-mTOR pathway in different tissues Note: Group A, blank control group; Group B, anesthetized rat model group; Group C, anesthetized rat model + PI3K/Akt agonist group; Group D, anesthetized rat model + PI3K/Akt antagonists group; Group E, PI3K/Akt agonist group. The comparison of mRNA expression of PI3K A. , AKT B. , mTOR C. and P70S6K D. in cerebral cortex, hippocampus, cerebellum, brain stem, and thalamus of rats among the five groups. The superscript lowercase letters ( a, b, c, d ) represent the pairwise comparison among the five groups with the same protein and tissue. The same superscript lowercase letter indicated the P > 0.05, and the different superscript lowercase letter indicated the P

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques: Expressing

Journal: Oncotarget

Article Title: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia

doi: 10.18632/oncotarget.10172

Figure Lengend Snippet: The dynamic changes of electrocorticogram (ECoG) in rats before and after drug administration Note: Group A. , blank control group; Group B. , anesthetized rat model group; Group C. , anesthetized rat model + PI3K/Akt agonist group; Group D. , anesthetized rat model + PI3K/Akt antagonists group; Group E . PI3K/Akt agonists group A: ECoG image of rats in Group A; B1-B2: ECoG image of rats in Group B at the time points of 5 min before (B1) and after (B2) drug administration; C1-C2: ECoG image of rats in Group C at the time points of 5 min before (C1) and after (C2) drug administration; D1-D2: ECoG image of rats in Group D at the time points of 5 min before (D1) and after (D2) drug administration; E1-E2: ECoG image of rats in Group E at the time point of 5 min before (E1) and after (E2) drug administration.

Article Snippet: Goat anti-rat monoclonal antibodies for PI3K, AKT, p-AKT, mTOR, p-mTOR, P70S6K and p-P70S6K were purchased from Santa Cruz Biotechnology (Santa Cruz, USA).

Techniques:

Journal: Molecular Medicine Reports

Article Title: Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK/AKT signaling pathway

doi: 10.3892/mmr.2018.8811

Figure Lengend Snippet: ERK/AKT signaling pathway is involved in the activation of the TNF/caspase-3 cascade within ovarian cancer cells. (A) Inhibition of ERKIR decreased caspase-3 expression levels within CAOV-3 cells compared with in the control group. (B) Inhibition of ERKIR inhibited TNF-induced CAOV-3 cell apoptosis compared with in the control group. (C) PL-PTX-induced CAOV-3 cell apoptosis was inhibited via an ERK inhibitor compared with in the control group. **P

Article Snippet: The primary antibodies used were against: Caspase-9 (1:1,200; ab32539), ERK (1:1,000; ab54230) and phosphorylayed (p)ERK 1/2 (phospho-Thr202/Tyr204; 1:1,000; ab214362), caspase-3 (1:1,200; ab2171), protein kinase B (AKT; 1:1,000; ab8805), p-AKT (phosphor-S473; 1:1,000; ab8932) and β-actin (1:500; ab8226; all Abcam) for 12 h at 4°C.

Techniques: Activation Assay, Inhibition, Expressing

Journal: eNeuro

Article Title: Reelin Counteracts Chondroitin Sulfate Proteoglycan-Mediated Cortical Dendrite Growth Inhibition

doi: 10.1523/ENEURO.0168-20.2020

Figure Lengend Snippet: CSPG-induced Akt dephosphorylation is counteracted by Reelin signaling. A , Cortical neurons were cultured for 2 DIV and stimulated for 1 h with CM or RM alone, or in conjunction with CSPGs (3 μg/ml) or Triciribine (TCBN; 1 μ m ). Western blotting of cortical neuron lysates probed for Reelin signaling proteins. P-Dab1 and Dab1 = ∼80 kDa, p-Akt and Akt = 60 kDa, p-Erk = 44 kDa, GAPDH = 38 kDa. Duplicates of each condition are shown. B–D , Quantification. E , F , Dab1 deficient neurons remain sensitive to CSPG-dependent dephosphorylation but exhibit blunted Akt phosphorylation in response to Reelin stimulation. Cells were immunolabeled with anti p-Akt (S473) and anti-DCX antibodies. p-Akt levels along the dendrites were quantified and normalized to the corresponding DCX signal. N ≥ 7 replicates in A , n = 25–35 neurons per group in E . Asterisks in C indicate comparison to CM; *, different at p

Article Snippet: The primary antibodies used were anti-MAP2 (1:250, Chemicon, ab5756), anti-SMI-312 (1:1000, Covance, SMI312R), anti-p-Akt (1:100, Santa Cruz, sc-514032), Cat-315 (1:20, from R. Matthews; ), CS56 (1:200, Abcam, ab11570), and anti-DCX (1:500, gift from C. Walsh; ) polyclonal sera.

Techniques: De-Phosphorylation Assay, Cell Culture, Western Blot, Immunolabeling

Journal: eNeuro

Article Title: Reelin Counteracts Chondroitin Sulfate Proteoglycan-Mediated Cortical Dendrite Growth Inhibition

doi: 10.1523/ENEURO.0168-20.2020

Figure Lengend Snippet: Reelin application counteracts CSPG-induced Akt dephosphorylation in developing neurites. E15 cortical neurons were cultures for 2 d and stimulated with Reelin (RM) or control (CM) media and/or CSPGs. Cells were immunolabeled with anti p-Akt (S473) and anti-DCX antibodies. p-Akt levels along the dendrites and somata were quantified and normalized to the corresponding DCX signal. Arrowheads point to p-Akt signal at dendritic tips; *, different at p

Article Snippet: The primary antibodies used were anti-MAP2 (1:250, Chemicon, ab5756), anti-SMI-312 (1:1000, Covance, SMI312R), anti-p-Akt (1:100, Santa Cruz, sc-514032), Cat-315 (1:20, from R. Matthews; ), CS56 (1:200, Abcam, ab11570), and anti-DCX (1:500, gift from C. Walsh; ) polyclonal sera.

Techniques: De-Phosphorylation Assay, Immunolabeling